Analyst Reco. United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
233.8 ^USD	-0.89%		-0.09%	+6.35%

Apr. 23	United Therapeutics Insider Sold Shares Worth $1,704,174, According to a Recent SEC Filing	MT
Apr. 23	United Therapeutics Q1 Results Could Fall Short of Market Expectations, Oppenheimer Says	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

United Therapeutics Insider Sold Shares Worth $1,704,990, According to a Recent SEC Filing	Apr. 19	MT
United Therapeutics Insider Sold Shares Worth $1,682,819, According to a Recent SEC Filing	Apr. 17	MT
United Therapeutics Insider Sold Shares Worth $1,707,775, According to a Recent SEC Filing	Apr. 15	MT
United Therapeutics Insider Sold Shares Worth $6,831,737, According to a Recent SEC Filing	Apr. 11	MT
United Therapeutics Insider Sold Shares Worth $4,727,736, According to a Recent SEC Filing	Apr. 09	MT
United Therapeutics Insider Sold Shares Worth $6,957,709, According to a Recent SEC Filing	Apr. 05	MT
United Therapeutics Insider Sold Shares Worth $1,394,248, According to a Recent SEC Filing	Apr. 04	MT
United Therapeutics Insider Sold Shares Worth $7,100,981, According to a Recent SEC Filing	Mar. 25	MT
United Therapeutics Insider Sold Shares Worth $1,418,726, According to a Recent SEC Filing	Mar. 22	MT
United Therapeutics Insider Sold Shares Worth $7,088,196, According to a Recent SEC Filing	Mar. 21	MT
Goldman Sachs Upgrades United Therapeutics to Neutral From Sell, Adjusts PT to $215 From $213	Feb. 12	MT
Leerink Partners Starts United Therapeutics with Outperform Rating, $330 Price Target	Feb. 05	MT
Wedbush Lifts United Therapeutics' PT to $308 From $307 After Higher-Than-Expected Q3 Revenue Driven by Tivaso Franchise; Keeps Outperform Rating	Nov. 02	MT
Morgan Stanley Adjusts Price Target on United Therapeutics to $318 From $316, Maintains Overweight Rating	23-08-03	MT
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $268 From $256, Maintains Buy Rating	23-08-03	MT
Wedbush Lifts United Therapeutics' Price Target to $307 From $305 After 'Strong' Q2 Results, Keeps Outperform Rating	23-08-03	MT
Ladenburg Thalmann Adjusts Price Target on United Therapeutics to $256 From $285, Maintains Buy Rating	23-05-04	MT
Argus Adjusts United Therapeutics' Price Target to $280 From $300, Keeps Buy Rating	23-04-21	MT
Morgan Stanley Trims Price Target on United Therapeutics to $316 From $320, Maintains Overweight Rating	23-04-10	MT
UBS Trims Price Target on United Therapeutics to $310 From $330, Keeps Buy Rating	23-04-10	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. United Therapeutics Corporation

Equities

UTHR

US91307C1027

Analyst Reco.

Filters